The University of Virginia is conducting a clinical research study for adults ages 18 and over who have relapsed/refractory hematologic malignancies. The purpose of this research study is to test the safety of PRT2527 at different dose levels alone or in combination with Zanubrutinib (also known as BFB-3111) to find out what effects, good and/ or bad, PRT2527 alone or PRT2527 taken together with Zanubrutinib has on you and your type of cancer. You will receive PRT2527 alone or in combination with Zanubrutinib. This study is open-label, which means that you and your study doctor will know what dose of study drug (PRT2527 or zanubrutinib) you will be taking. Study treatments are divided into cycles. Cycle 1 will last between 21 and 35 days. All other cycles will last 21 days. PRT2527 will be given via an IV infusion. Zanubrutinib will be taken orally via a capsule.
The length of your participation in this study will vary depending on how your body reacts to the study drug, PRT2527. Your participation in this study could last for approximately 2 years.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/study/NCT05665530
The study team may arrange for your hotel, or you may be reimbursed by check up to $200 per night for a hotel. You may also receive up to $.54 cents per mile.
No Compensation